glp-1 drugs risks and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology TrimRX | Why GLP-1 Medications
Description
Insurance plans place GLP-1 drugs into different coverage tiers, often requiring prior authorization or high out-of-pocket costs
In the subgroup analyses, human GLP-1 RAs, but not nonhuman GLP-1 RAs, reduced the risk of MACE in patients with HF (p interaction = 0.11)
As global demand rises for effective metabolic therapies, GLP-1 drug development remains one of the fastest-growing segments in biopharma innovation
Incretin Agents
Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.
Hence, there is a critical need to enhance our understanding through pharmacological management, which unfortunately remains limited
